Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NORDAX BANK WINNER OF BRILLIANT AWARDS FOR BEST CUSTOMER SERVICE IN THE INDUSTRY

Stockholm 22 February 2024: Nordax Bank, a part of NOBA Bank Group, ranks in top when 2,3 million people are asked which bank in Sweden that provides the best customer service. Nordax Bank has managed to maintain an average customer satisfaction rate of 93.2% among its own customers during 2023. A clear success factor is the employee’s engaging approach. The survey is conducted by the analysis firm Brilliant Future.“Even though we have been in the absolute top for several years, our goal has always been to become the best. The key has been a systematic and goal-oriented work overtime that

Notice of Extraordinary General Meeting in Dignitana AB (publ)

NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail.   The shareholders of Dignitana AB (publ) reg. no. 556730-5346 (the “Company”) are hereby given notice to attend the Extraordinary General Meeting (the “EGM”) on 12 March 2024 at 15.00 CET at Turning Torso, Lilla Varvsgatan 14, 211 15 in Malmö. Registration starts at 14.30 CET.   Right to participate Shareholders that wish to participate in the EGM shall be registered in the share register maintained by Euroclear Sweden AB no later than on 4

BioStock: Ultimovacs receives Orphan Drug Designation from EMA

Ultimovacs has been granted Orphan Drug Designation from the European Medicines Agency for its universal cancer vaccine, UV1, as a treatment for mesothelioma, a rare and aggressive form of cancer with limited therapeutic options. The designation was granted based on results from the phase II clinical trial NIPU and brings regulatory and commercial benefits to the development of the immunotherapy. BioStock reached out to CEO Carlos de Sousa for a comment.Read the interview with Carlose de Sousa at biostock.se: Ultimovacs receives Orphan Drug Designation from EMA - BioStock 

The 2024 Playbook for Authentic Engagement in Competitive Gaming

The free-to-download whitepaper presents a comprehensive guide for brands and organizations looking to engage with competitive gaming audiences in an authentic way. Stockholm, February XX, 2024: Leading esports platform Challengermode and sponsorship analytics company Shikenso Analytics have teamed up to publish their "2024 Playbook for Authentic Engagement in Competitive Gaming." IntroductionIn the dynamic landscape of gaming and esports, authenticity is not just desirable; it's a non-negotiable prerequisite for brands aiming to build meaningful connections with gamers. This

AstraZeneca prices a $5bn bond offering

22 February 2024 07:00 GMT AstraZeneca prices a $5bn bond offering AstraZeneca PLC ("AstraZeneca") announces that its wholly owned subsidiary AstraZeneca Finance LLC, priced a four tranche global bond offering totalling $5bn on 21 February 2024. The offering is expected to close on 26 February 2024, subject to customary closing conditions. The transaction, which is a global offering registered with the US Securities and Exchange Commission ("SEC"), consists of the following four tranches: Notes issued by AstraZeneca Finance LLC and fully and unconditionally guaranteed by

Beyond Frames Entertainment AB (publ) Year-End report Q4 2023

Fourth quarter, October 1 – December 31, 2023 · Sales amounted to 40,386 (4,239) kSEK, an increase of 853% compared to Q4 2022. · Operating profit before depreciation and amortization and shares in associated companies' earnings (EBITDA) amounted to 3,853 (-5,186) kSEK · Profit after financial items amounted to -3,749 (-7,840) kSEK · EBITDA per share amounted to 0.22 (-0.30) SEK · Profit per share after financial items amounted to SEK -0.22 (-0.46) SEK · Cash and cash equivalents at the end of the quarter amounted to 21,820 (48,309) kSEK. This compares to 34,555 kSEK at

Arla Plast AB Year-end report 2023

STABLE CLOSE TO A SUCCESSFUL YEAROCTOBER – DECEMBER 2023 · Sales volume amounted to 4,328 tonnes (4,124 tonnes) an increase by 5%. · Net sales amounted to SEK 226.6 million (SEK 232.0 million), a decline by 2%. The organic decline was 3%. · Operating profit amounted to SEK 16.0 million (SEK 11.3 million), an increase by 42%. · The operating margin increased to 7.1% (4.9%). · Profit for the period amounted to SEK 9.1 million (SEK 8.6 million) an increase by 6%. · Earnings per share before dilution amounted to SEK 0.43 (SEK 0.43), and after dilution to SEK 0.43 (SEK 0.41).

Tender Offer

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.   Fidelity Emerging Markets Limited (the “Company”) Legal Entity Identifier: 213800HWWQPUJ4K1GS84   Launch of Tender Offer   Further to its announcement on 27 November 2023, the board of directors of the Company (the “Board”) today announces that it will proceed with making a tender offer for up to 14.99 per cent.

Acroud publishes interim report Oct-Dec 2023: A mixed quarter full of activity

Financial highlights during fourth quarter 2023   Revenue amounted to EUR 9 905 (10 019) thousand, which remained in line with the previous year.   · Adjusted EBITDA (before items affecting comparability) was EUR 1 405 (2 492) thousand decreasing by 44% year-on-year and increasing 20% quarter-on-quarter. EBITDA amounted to EUR 1 810 (2 342) thousand, decreasing by 23% year-on-year and increasing by 92% quarter-on-quarter. · Profit after tax was EUR -8 008 (-20 265) thousand. Adjusted profit after tax (before items affecting comparability and currency effects) was EUR -409 (

Gradientech: Year-end report 2023

Gradientech AB (publ) year-end report for 2023 is now available on the company's website www.gradientech.se.Fourth quarter 2023 · Net sales amounted to SEK 376 thousand (831). · Net profit/loss amounted to SEK -17,810 thousand (-16,409). · Earnings per share before and after dilution were SEK -1.00 (-1.03). · Cash flow from operating activities amounted to SEK -14,637 thousand (-19,550). · Cash and cash equivalents amounted to SEK 10,811 thousand (21,177) as of December 31, 2023. · Equity amounted to SEK 48,451 thousand (46,578) as of December 31, 2023. · In October,

Year-end report January - December 2023: Favourable conditions for continued growth

With strong earnings and a stable balance sheet, Catena’s prospects for further developing its already strong position are optimal.22 February 2024, 8.00 a.m. CEST · Rental income rose by 17 percent to SEK 1,808 million (1,544). · The net operating surplus increased by 19 percent to SEK 1,447 million (1,220). · Profit from property management rose by 16 percent to SEK 1,107 million (954). · Profit from property management per share rose by 4 percent to SEK 22.15 (21.35). · The change in value of properties amounted to SEK 524 million (865). · Profit for the year

Tecnotree Corporation Full Year Financial Report 1[st] Jan – 31[st] December 2023 (unaudited)

Tecnotree Corporation Stock Exchange Release 22 February 2024 at 9:00 EETRECORD DEMAND FOR TECNOTREE PRODUCTS, DELIVERS REVENUE GROWTH ABOVE GLOBAL MARKET TRENDS Fourth quarter (October – December 2023) · Net sales increased 10.4% to EUR 22.2 (20.1) million. · Operating result increased 29.5% to EUR 7.9 (6.1) million. · Flat operating cost EUR 14.3 (14.0) million · Foreign exchange losses increased 161% to EUR 6.0 (2.3) million. · Result for the period decreased by 26.4% mainly due to higher exchange loss to EUR 2.4 (3.2) million. · Operating Cash flow EUR 4.7 (0.6)

Platzer’s Annual Report 2023 published

Platzer’s Annual Report in Swedish is now published. The English version will be published during the month of March. The Annual General Meeting of Platzer Fastigheter Holding AB (publ) will take place on Wednesday, 20 March, 2024. For further information please contact: Johanna Hult Rentsch, CEO, Platzer, tel: +46(0)709-99 24 05 Fredrik Sjudin, CFO, Platzer, tel: +46(0)721-27 77 78 This information is information that Platzer Fastigheter Holding AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted, for publication on 22

Kährs Group: Year-End Report 2023

Optimisation for continued stable profitability in a challenging market situationKährs’ net sales decreased by 35 per cent in the fourth quarter, primarily due to continued weak demand in the residential segment compared to record-strong comparative figures. Profitability was maintained by adapting the production capacities to lower demand and good cost control. The strong trend of improved gross margin was broken in the last quarter of the year, with both operating EBITA and operating EBITA% decreasing compared to the historically strong fourth quarter in 2022. Strong cash flow despite a

Ratos company SSEA to initiate pilot project in carbon-neutral construction together with MKB Fastighets AB

The construction company SSEA, which is part of SSEA Group, is initiating a pilot project in sustainable construction together with MKB Fastighets AB. The pilot project involves the construction of 12 new apartments in Malmö. MKB Fastighets AB’s ambition with the project, known as Rapsen 2, is to enhance its expertise in sustainable construction and test construction methods using a cross-laminated timber frame. The goal is for the project to emit a maximum of 207 kg CO2/sqm and thus reach below the LFM30 target limit value for housing, a project with a low climate impact. In the next step

Everysport Group publishes Year-End Report 2023: Increased growth focus, new record quarter for Elite Prospects

Summary Q4 2023 (compared to Q4 2022) · The Group's net sales amounted to SEK 29.9 million (48.0), excluding divested operations, net sales increased 11 percent to SEK 25.7 million (23.2). · Net sales for business area Elite Prospect increased by 33 percent to SEK 10.6 million (8). Monthly Recurring subscription-based Revenue (MRR) increased by 50 percent to SEK 2.25 million (1.50). · Net sales for business area Everysport amounted to SEK 17.2 million (38.8), of which SEK 4.2 million relates to divested operations. · The Group's adjusted operating result, EBITDA, was SEK 2.1

Interim Report Fourth Quarter 2023

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2023 – 31.12.2023. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ”Stenocare has successfully managed to grow sales to patients during 2023, and in Q4, our financial and commercial platform grew stronger. Gross sales for the fourth quarter of 2023 were 1.7 mDKK, which

Year-end report Quartiers Properties 2023

Quartiers Properties AB (publ) today publishes the company's year-end report for 2023.EBITDA adjusted for previous revaluations of sold apartments: SEK 106.9 million.   January - December 2023 · Net sales amounted to 329 790 (203 387) TSEK, corresponding to a growth of 62%. · Operating profit before depreciation (EBITDA) amounted to SEK 55,225 (-7,208) thousand, corresponding to an improvement of SEK 62,433 thousand compared to the previous year. EBITDA adjusted for previous revaluations of apartments sold during the period totalled SEK 106,853 thousand. · Revenue from

Zengun Group AB (publ) Full Year Report January - December 2023

“Despite the industry’s challenges, Zengun posted its highest turnover to date. Turnover for the year totalled MSEK 2,771, and EBITDA totalled MSEK 123.” Mick Salonen, President and CEO Fourth quarter •         Net turnover amounted to MSEK 781.3 (742.7) •         EBITDA totalled MSEK 33.9 (26.0), corresponding to an EBITDA margin of 4.3% (3.5) •         Earnings before tax amounted to MSEK 16.9 (14.1) •         Operating cash flow was MSEK 15.2 (67.7) •         Orders received totalled MSEK 722.6 (159.6) •         The order book amounted to MSEK 2,791.7 (3,633.1)

Transaction in Own Shares

    22 February 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |21/02/2024|+----------------------------------------------------------

Zwipe H2 2023 Report – new focus on Zwipe Access

OSLO, NORWAY – 22 February 2024 – Zwipe AS ("Zwipe" or "the company") today announces its results for the first half of 2023. Highlights H2 2023 · Zwipe successfully completes rights issue in December raising NOK 35 million in gross capital, with a possible exercise of warrants in December 2024 representing the potential for up to NOK 39 million in additional funds. · Cash position after full receipt of funds in December 2023 / January 2024 at NOK 66.6 million. · Slower than expected market adoption of biometric payment cards, but significant traction in Zwipe Access.

Year-End Report and report for the fourth quarter for January 1, 2023 to December 31, 2023

· Net turnover in the period amounted to 52 075 TSEK (27 738 TSEK). Net turnover in the fourth quarter amounted to 19 685 TSEK (7 492 TSEK). · Earnings before interest and taxes (EBIT) amounted to -29 869 TSEK (-24 092 TSEK). Earnings before interest and taxes (EBIT) in the fourth quarter amounted to -11 802 TSEK (-10 287 TSEK) · The result after financial items amounted to -34 079 TSEK (-31 377 TSEK). The result after financial items in the fourth quarter amounted to -10 407 TSEK (-13 924 TSEK). · The result per share amounted to -0,073 SEK (-0,21 SEK) in the period. The

BioArctic's CEO Gunilla Osswald Winner of The Arthur D. Little Nordic Life Science Award

Stockholm, Sweden, February 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today proudly announced that CEO, Gunilla Osswald, has been awarded the Arthur D. Little Nordic Life Science Award. This recognition is given to individuals in the Nordic region who demonstrate extraordinary leadership within the Life Science industry.The jury cited Gunilla Osswald’s "high-caliber leadership qualities" as the foundation for her award, highlighting her ability to foster "a shared ambition, inclusiveness, and sense of purpose" throughout the company and with stakeholders. These efforts have

There are no items matching the current filter
There are no more items matching the current filter
Back to top